Clinical trial
A Multicenter, Open Phase I Study to Evaluate the Safety and Pharmacokinetic Profile of F01 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
NCT06206902 is registered in ClinicalTrials.gov with Shanghai Simnova Biotechnology Co.,Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Open Phase I Study to Evaluate the Safety and Pharmacokinetic Profile of F01 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma
- Lead sponsor
- Shanghai Simnova Biotechnology Co.,Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- April 30, 2024
- Completion date
- December 31, 2025
- Enrollment
- 55 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
non-hodgkin's lymphoma